Clinical-stage immunology and inflammation biotech
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 75 | New buy | 1,173,396 | $14,949,065 | 0.0% |
| Carlyle Group Inc. (auto-surfaced) | 44 | Trimmed -95% | 60,363 | $769,020 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-05-06 | SCHEDULE 13D/A | ORBIMED ADVISORS LLC | 13.3% | High | filing |
| 2026-03-12 | SCHEDULE 13D/A | ORBIMED ADVISORS LLC | 15.4% | High | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-10-17.